Does Semaglutide Extend Lifespan? What the New Mouse Study Actually Shows
The concise answer
Short answer: No human lifespan benefit has been shown. A peer-reviewed Nature study published September 2, 2026, found that older female mice given semaglutide had a median lifespan of 834 days, compared with 742 days in control mice. The lifespan experiment included 40 semaglutide-treated mice and 39 controls.
That is a meaningful preclinical finding. It is not evidence that semaglutide extends human life, reverses human aging, or should be used as an anti-aging treatment. The researchers and the National Institutes of Health both say that dedicated long-term human studies would be needed.
Last reviewed: September 8, 2026.
What did the semaglutide lifespan study test?
Researchers at the University of California, Berkeley studied 20-month-old female C57BL/6 mice. One lifespan group received semaglutide by daily subcutaneous injection; a control group received saline. Treatment continued for the rest of the animals’ lives.
The design matters because the headline result comes from one animal model, one sex, one strain, and a laboratory regimen. The study did not enroll people, test a marketed semaglutide product as prescribed to patients, or evaluate whether a human treatment schedule changes lifespan.
| Study detail | What the paper reports |
|---|---|
| Model | 20-month-old female C57BL/6 mice |
| Lifespan cohort | 39 saline controls and 40 semaglutide-treated mice |
| Treatment timing | Started late in life and continued for the lifespan experiment |
| Median lifespan | 742 days in controls; 834 days with semaglutide |
| Food intake | 24% lower with semaglutide in a separate metabolic-measurement cohort |
| Human participants | None |
Separate cohorts were used for many of the physiological, cellular, and molecular measurements. Another separate experiment compared semaglutide with matched calorie restriction for five months, using 10 mice per group. Those distinctions prevent the different experiments from being blended into one larger human-like trial.
The study was supported by National Institute on Aging grants and the National Institute of Food and Agriculture. The paper also discloses that the Regents of the University of California filed patent application 64/113,481 covering GLP-1 receptor agonists for healthy ageing. That disclosure does not determine whether the findings are valid, but it is relevant context for readers evaluating the work.
What did the researchers find?
The clearest outcome was the difference in median lifespan: 834 days in the semaglutide group versus 742 days in controls. That is a 92-day difference, or about 12% relative to the control median. It describes the middle of each group’s survival distribution; it does not mean every treated mouse lived 92 days longer.
In the separate functional and laboratory experiments, semaglutide-treated mice also performed better on measures related to movement, muscle function, spatial memory, and glucose control. The investigators reported changes in several biological features associated with aging, including inflammation, cellular senescence, mitochondrial function, proteostasis, and regenerative capacity.
These findings can help researchers form mechanistic hypotheses. They do not turn a mouse biomarker into a demonstrated human clinical benefit.
Does this prove that semaglutide extends human lifespan?
No. The paper establishes an effect in the studied mice under the studied conditions. Translation to people remains unknown.
- Species: mouse aging and human aging do not progress identically.
- Population: the lifespan experiment used only older female mice of one laboratory strain.
- Regimen: the animals received a defined daily laboratory regimen, not a human prescribing schedule.
- Outcome: no human survival, healthspan, or validated aging endpoint was measured.
- Scale: the lifespan comparison involved 79 mice, while several mechanistic analyses used smaller separate cohorts.
NIH summarized the result as evidence from an animal model and expressly cautioned that similar effects cannot be assumed in humans. The Nature authors likewise wrote that long-term clinical studies designed around aging-related outcomes in older populations would be required.
The current FDA-approved Wegovy prescribing information lists specific indications; longevity or anti-aging is not among them. The label should be read for the product’s approved uses, contraindications, warnings, and precautions. This article is not a treatment or dosing guide.
Was the result simply caused by eating less?
The study was designed in part to explore that question, but it does not reduce to a simple yes or no.
Semaglutide reduced food intake by 24%. In a separate five-month experiment, researchers matched a calorie-restricted group to that reduction. Both semaglutide and calorie restriction produced similar losses of body weight and fat and preserved several measures of physical function compared with controls.
The groups were not identical. The paper reports that semaglutide produced more favorable trajectories than calorie restriction for exploratory behavior, spatial memory, and glucose control. The authors therefore describe GLP-1 receptor activation as having effects that may extend beyond reduced calorie intake.
Still, the calorie-restriction comparison was a small, separate functional study—not a human trial and not a calorie-restriction lifespan comparison. It supports a mechanism for further study; it does not prove that semaglutide is a human “calorie-restriction mimetic” with longevity benefits.
What does “slowed aging” mean in this paper?
In this study, “slowed aging” refers to the combined pattern observed in the mice: longer median survival, preserved or improved performance on several functional tests, and changes in molecular or cellular measures associated with aging.
It does not mean that researchers measured a single universal “biological age” and proved that it moved backward. Nor does it establish that each molecular change caused the survival difference. Multiple experimental layers point in the same direction, but the causal chain still requires study.
What about safety?
The investigators reported no adverse effects attributable to semaglutide within the endpoints they monitored in the mice. That statement is narrower than “semaglutide is safe for anti-aging use.”
A preclinical lifespan experiment cannot replace the much larger body of product-specific human safety evidence, approved labeling, clinical monitoring, or individualized medical judgment. It also cannot establish the safety of compounded, research-use, or otherwise unapproved materials. Our separate article explains why reports associated with compounded semaglutide require their own careful interpretation.
What evidence would answer the human question?
A credible human longevity claim would require evidence designed for people rather than inference from animal results. Useful next steps could include:
- Prospective human studies with aging-related outcomes defined before analysis.
- Long follow-up capable of separating short-term weight or glucose changes from durable healthspan effects.
- Appropriate comparator groups and careful control of baseline disease, body composition, diet, and other medications.
- Populations broad enough to examine age, sex, health status, and treatment-response differences.
- Safety analyses suited to older adults and long treatment duration.
- Replication by independent research groups.
Human observational studies or post-hoc analyses can identify promising signals, but they generally cannot establish that a medicine caused longer life. Randomized evidence with prespecified endpoints would be more informative.
The same evidence boundary appears across peptide research: animal findings, mechanistic studies, registered human trials, and completed clinical results answer different questions. See our MOTS-C evidence overview and MOTS-MET human-trial analysis for another example.
Frequently asked questions
Does semaglutide extend lifespan?
It extended median lifespan in the older female mice studied. Whether semaglutide extends lifespan in humans is unknown.
Did the study show that Ozempic slows aging?
No. The experiment tested semaglutide in mice, not the effect of branded Ozempic treatment on human aging or survival. A result involving the same active ingredient cannot be converted into a human product claim.
Were humans included in the 2026 Nature study?
No. The lifespan arm involved 79 female mice: 39 controls and 40 treated with semaglutide.
Does the study support taking semaglutide for longevity?
No. It supports further research. It does not establish a human longevity benefit, an anti-aging indication, or a self-treatment rationale.
The bottom line
The new Nature paper reports a real and notable result: semaglutide increased median lifespan in older female mice from 742 to 834 days and was associated with several functional and biological changes linked with aging.
The accurate headline needs its second half. This was a preclinical mouse study. It does not show that semaglutide extends human life, prove an anti-aging effect in people, or justify use outside evidence-based medical care.
Explore the JD BioWorks Research Library for source-linked explanations of peptide and metabolic research. Our sourcing approach is described in our Scientific Sourcing and Editorial Standards.
Primary sources
- Feng Y, et al. Late-life semaglutide treatment slows ageing and extends lifespan in female mice. Nature. Published September 2, 2026. doi:10.1038/s41586-026-10940-7.
- National Institutes of Health. GLP-1 treatment late in life extends lifespan in animal model. September 2, 2026.
- U.S. Food and Drug Administration. Wegovy prescribing information. Current June 2026 label reviewed for approved-use context.
Research-use and editorial disclaimer: This article summarizes publicly available preclinical research for educational purposes. It is not medical advice, a dosing guide, or a recommendation to use semaglutide or any other substance for longevity. Prescription decisions belong between patients and licensed clinicians using current product labeling and individual clinical information. JD BioWorks materials are intended solely for qualified laboratory research and are not for human or veterinary use. Review the full research-use disclaimer.